The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis
Abstract
Background: Most disease‐modifying therapies (DMTs) for multiple sclerosis (MS) are self‐injectable medications that must be taken on an ongoing basis to reduce disease activity. Thus, adherence to therapy becomes an important challenge that must be addressed to maximize benefits of therapy. This study evaluated rates of adherence to prescribed treatment and explored factors affecting adherence amongst patients with relapsing‐remitting MS. Methods: This was an observational, multicenter, multinational, phase 4 study. Patients and physicians received paper questionnaires regarding adherence to DMTs approved at the time of the study, including intramuscular interferon beta‐1a (IFNβ‐1a), subcutaneous IFNβ‐1a, IFNβ‐1b, and glatiramer acetate. Quality of life and cognition data also were collected. Multivariate analysis was conducted to identify factors associated with adherence to long‐term DMTs. Results: Two thousand six hundred and forty‐eight patients were studied, revealing an average treatment duration of 31 months. Seventy‐five percent of patients (n = 1923) were adherent to therapy. The most common reasons for non‐adherence were forgetting to administer the injection (50.2%) and other injection‐related reasons (32.0%). Adherent patients reported better quality of life (P < 0.05) and fewer neuropsychological issues (P < 0.001) than non‐adherent patients. Adherent patients had significantly shorter duration of disease (P < 0.001) and shorter duration of therapy (P = 0.005) than non‐adherent patients. Women were more likely than men to adhere to treatment. Conclusion: Identifying factors that affect adherence to prescribed treatments is the first step in improving adherence of patients with MS to therapy, thereby helping maximize the benefits of long‐term DMTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adherence to Long-Term Therapies: Evidence for Action
De Geest, S., & Sabaté, E. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,272
Adherence to Long‐Term Therapies: Evidence for Action
Burkhart, P. V., & Sabaté, E. (2003) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2003.tb00001.x · Cited by 2,526
Cognitive dysfunction in multiple sclerosis.: I. Frequency, patterns, and prediction
Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991) · Neurology · doi:10.1212/wnl.41.5.685 · Cited by 2,110
Disease Steps in multiple sclerosis: A simple approach to evaluate disease progression
Hohol, M. J., Orav, E. J., & Weiner, H. L. (1995) · Neurology · doi:10.1212/wnl.45.2.251 · Cited by 551
Depression and multiple sclerosis
Sadovnick, A. D., Remick, R. A., Allen, J., Swartz, E., Yee, I. M. L., Eisen, K., Farquhar, R., Hashimoto, S. A., Hooge, J., Kastrukoff, L. F., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.628 · Cited by 532
Cognitive Dysfunction in Multiple Sclerosis
Guimarães, J., & Sá, M. J. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00074 · Cited by 427
Benedict, R. H., Munschauer, F., Linn, R., Miller, C., Murphy, E., Foley, F., & Jacobs, L. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms861oa · Cited by 345
Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis
Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550170015009 · Cited by 307
Factors that influence adherence with disease-modifying therapy in MS
Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J., Jeffery, D., Cohen, B., Mankowski, K., Guarnaccia, J., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0096-y · Cited by 258
Self-citationInterrupted therapy: Stopping and switching of the β-interferons prescribed for MS
Tremlett, H. L., & Oger, J. (2003) · Neurology · doi:10.1212/01.wnl.0000078885.05053.7d · Cited by 208
Cited by
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
McKeith, I. G., Ferman, T. J., Thomas, A. J., Blanc, F., Boeve, B. F., Fujishiro, H., Kantarci, K., Muscio, C., O'Brien, J. T., Postuma, R. B., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009323 · Cited by 777
Self-citationConfavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
Vermersch, P., Czlonkowska, A., Grimaldi, L. M., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benamor, M., Bauer, D., Truffinet, P., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513507821 · Cited by 354
Self-citationReaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
PatientConcept App: Key Characteristics, Implementation, and its Potential Benefit
Lang, M., Mayr, M., Ringbauer, S., & Cepek, L. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-0133-4 · Cited by 14
Metadata
- Authors
- Devonshire, V., Lapierre, Y., Macdonell, R., Ramo‐Tello, C., Patti, F., Fontoura, P., Suchet, L., Hyde, R., Balla, I., Frohman, E. M., Kieseier, B. C., & for the GAP Study Group
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2010-12-15
- Volume
- 18
- Issue
- 1
- Pages
- 69-77
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W1581887055
- Cited by
- 340
- References
- 26
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis. https://app.cochat.ai/papers/10.1111/j.1468-1331.2010.03110.x
- The paper
- Devonshire, V., Lapierre, Y., Macdonell, R., Ramo‐Tello, C., Patti, F., Fontoura, P., Suchet, L., Hyde, R., Balla, I., Frohman, E. M., Kieseier, B. C., & for the GAP Study Group. (2011). The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2010.03110.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.